CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage...
-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and...
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a...
- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.